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Mycobacterium
tuberculosis Drug
Resistance,
Abkhazia
To the Editor: Drug-resistant
tuberculosis (TB) has been identified
as a major problem in the former
Soviet Union, and was recently sur-
veyed in the Aral Sea regions of
Dashoguz (Turkmenistan) and
Karakalpakstan (Uzbekistan) (1).
However, few data are available for
the Caucasian region and published
reports have focused mainly on pris-
ons (2,3).
We report a drug resistance survey
for first- and second-line anti-TB
drugs conducted in Abkhazia, a
Caucasian region of 8,600 km2 with
approximately 250,000 inhabitants, at
the western end of Georgia on the
Black Sea. The collapse of the Soviet
Union lead to disruption of TB control
activities in all Eastern bloc regions
(4). In Abkhazia, the shortage and
poor quality of drugs, self-medication,
and poor adherence to the therapy
became even more evident during the
war with Georgia in 1993 and the
international embargo that followed. A
TB program based on the World
Health Organization/International
Union against Tuberculosis and Lung
Disease (WHO/IUATLD) recommen-
dations was initiated in Abkhazia with
the support of Médecins Sans
Frontières (MSF) in 1999. In 2000,
monitoring of drug resistance was
started for new cases and previously
treated case-patients. The study was
performed in collaboration with
the Guliripchi TB Hospital, MSF,
and the Istituto Superiore di Sanità
(ISS), a WHO/IUATLD Supranational
Reference Laboratory for anti-TB
drug resistance.
Sputa were collected from all case-
patients attending Gulirip-chi TB
Hospital in Sukhumi, the capital of
Abkhazia, from September 2000 to
April 2004. Patients were either
referred by their practitioners or came
spontaneously because TB was sus-
pected. Diagnosis, treatment, and hos-
pitalization were provided free.
Samples were treated as previously
described (5). Of 489 sputa collected
from individual patients, 447 were
culture positive (246 from new case-
patients and 201 from previously
treated case-patients) and 42 were
culture negative; of these, >90%
showed a negative, doubtful, or 1+
smear result. Susceptibility to first-
line (streptomycin, isoniazid, rifam-
pin, and ethambutol) and second-line
(kana-mycin, ethionamide, capre-
omycin, cycloserine, p-aminosalicylic
acid, and ofloxacin) drugs was deter-
mined by the proportion method on
Middlebrook 7H10 agar. The critical
concentrations used were strepto-
mycin, 2 µg/mL; isoniazid, 0.2
µg/mL; rifampin, 1 µg/mL; ethambu-
tol, 5 µg/mL; kanamycin, 5 µg/mL;
ethionamide, 5 µg/mL; capreomycin,
10  µg/mL;  p-aminosalicylic acid,
2  µg/mL; and ofloxacin, 2 µg/mL
(6–8). Cycloserine was used at a con-
centration of 30 µg/mL (9). If a strain
was resistant to >1 first-line drugs, the
susceptibility to all second-line drugs
was determined.
Data on resistance to the first- and
second-line drugs are given in the
Table. The strains isolated from 35.8%
of the new case-patients and 57.2% of
the previously treated case-patients
were resistant to >1 first-line drugs.
The highest monoresistance was seen
for isoniazid and streptomycin in both
new and previously treated case-
patients while  monoresistance to
rifampin and ethambutol was low
(<1%). Multidrug-resistant (MDR)
strains (i.e., strains resistant to at least
isoniazid and rifampin) were observed
in 4.9% of the new cases and 25.4% of
the previously treated case-patients.
Strains resistant to isoniazid and strep-
tomycin were isolated from 6.9% of
the new cases and 8% of the previous-
ly treated case-patients. Resistance to
second-line drugs was high (15.9% in
new cases and 35.7% in previously
treated case-patients), with the highest
values being observed for kanamycin
(4.5% in new cases and 21.7% in pre-
viously treated case-patients) and
ethionamide (8% in new cases and
16.5% in previously treated case-
patients). Twenty-five percent and
52.9% of the MDR strains isolated
from new and previously treated case-
patients, respectively, showed resist-
ance to >1 second-line drugs. 
Few data have been reported on
drug resistance to first- and second-
line drugs in the former Soviet Union
and in the Caucasian region (1–4).
Overall, in Abkhazia, monoresistance
to isoniazid was higher than in
Karakalpakstan and Dashoguz (1),
while monoresistance to streptomycin
was lower. MDR-TB in new and pre-
viously treated case-patients showed
levels intermediate between these
2 regions. Resistance to kanamycinLETTERS
and ethionamide was 14.3% and
12.8%, respectively, while resistance
to ofloxacin was low (1.5%).
Fluoroquinolones have not been com-
monly used in Abkhazia and former
regions of the Soviet Union.
Currently, regimens for the treatment
of MDR-TB in Abkhazia combine an
intensive phase for a minimum of 6
months with at least 4 drugs to which
the MTB strain is susceptible, includ-
ing 1 parenteral agent and 1 fluoro-
quinolone (ofloxacin), followed by a
continuation phase of at least 15
months with ≥ 3 drugs. 
This is the first survey reporting
drug susceptibility data for MTB
within the Caucasus. It indicates that
the prevalence of MDR strains is
similar to that in other central Asia
regions (1). Our results are represen-
tative of the present situation in
Abkhazia since sampling systemati-
cally covered all TB cases for the
period examined. The Guliripchi TB
Hospital of Sukhumi is the only TB
treatment center in the region, and all
cases were included in the study.
Overall, our data show that second-
line drug resistance is present in
Abkhazia, particularly among cases
with MDR, and suggest the adoption
of strategies for access and correct use
of second-line drugs (10).
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Endogeneity in
Logistic
Regression Models 
To the Editor: Ethelberg et al. (1)
report on a study of the determinants
of hemolytic uremic syndrome result-
ing from Shiga toxin–producing
Escherichia coli. The dataset is rela-
tively small, and the authors use step-
wise logistic regression models to
detect small differences. This indi-
cates that the authors were aware of
the limitations of the statistical power
of the study. Despite this, the study
has an analytic flaw that seriously
reduces the statistical power of the
study.
An often overlooked problem in
building statistical models is that of
endogeneity, a term arising from
econometric analysis, in which the
value of one independent variable is
dependent on the value of other pre-
dictor variables. Because of this endo-
geneity, significant correlation can
exist between the unobserved factors
contributing to both the endogenous
independent variable and the depend-
ent variable, which results in biased
estimators (incorrect regression coef-
ficients) (2). Additionally, the correla-
tion between the dependent variables
can create significant multicollineari-
ty, which violates the assumptions of
standard regression models and
results in inefficient estimators. This
problem is shown by model-generated
coefficient standard errors that are
larger than true standard errors, which
biases the interpretation towards the
null hypothesis and increases the like-
lihood of a type II error. As a result,
the power of the test of significance
for an independent variable X1 is
reduced by a factor of (1-r2
(1|2,3,….)),
where r(1|2,3,….) is defined as the multi-
ple correlation coefficient for the
model X1 = f(X2,X3,…), and all Xi are
independent variables in the larger
model (3,4).
The results of this study clearly
show that the presence of bloody diar-
rhea is an endogenous variable in the
model showing predictors of hemolyt-
ic uremic syndrome, in that the diar-
rhea is shown to be predicted by, and
therefore strongly correlated with,
several other variables used to predict
hemolytic uremic syndrome.
Similarly, Shiga toxin 1 and 2 (stx1,
stx2)  genes are expected to be key
predictors of the presence of bloody
diarrhea, independent of strain, due to
the known biochemical effects of that
toxin (5,6). Because the strain is in
part determined by the presence of
these toxins, including both strain and
genotype in the model means that the
standard errors for variables for the
Shiga-containing strains and bloody
diarrhea symptom are likely to be too
high, and hence the significance lev-
els (p values) obtained from the
regression models are higher than the
true probability because of a type I
error. 
This flaw is a particular problem
with studies that use a conditional
stepwise technique for including or
excluding variables. The authors note
that they excluded variables from the
final model if the significance in ini-
tial models for those variables was
less than an α level (p value) of 0.05.
Given the inefficiencies due to the
endogeneity of bloody diarrhea, as
well as those that may result from
other collinearities significant predic-
tors were likely excluded from the
study, although this cannot be con-
firmed from the data presented. 
The problems associated with the
endogeneity of bloody diarrhea can be
overcome by a number of approaches.